[
  {
    "ts": null,
    "headline": "Top Midday Gainers",
    "summary": "PepGen (PEPG) shares rose Thursday after the company said late Wednesday it achieved the highest mea",
    "url": "https://finnhub.io/api/news?id=5e976cd1bdaaf2da90b516ba4868a917c24f592edeea73c7185e1b29d4f39d61",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758818196,
      "headline": "Top Midday Gainers",
      "id": 136884283,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "PepGen (PEPG) shares rose Thursday after the company said late Wednesday it achieved the highest mea",
      "url": "https://finnhub.io/api/news?id=5e976cd1bdaaf2da90b516ba4868a917c24f592edeea73c7185e1b29d4f39d61"
    }
  },
  {
    "ts": null,
    "headline": "MSD pays up to nearly $600m for Evaxion’s mystery vaccine candidate",
    "summary": "Evaxion’s preclinical asset targets an unknown infectious disease in which there are no other vaccines available.",
    "url": "https://finnhub.io/api/news?id=30311d4a2f3b9624f69223de2262f53049f6f8bf608a9160b5199160a23c7f35",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758818121,
      "headline": "MSD pays up to nearly $600m for Evaxion’s mystery vaccine candidate",
      "id": 136885624,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Evaxion’s preclinical asset targets an unknown infectious disease in which there are no other vaccines available.",
      "url": "https://finnhub.io/api/news?id=30311d4a2f3b9624f69223de2262f53049f6f8bf608a9160b5199160a23c7f35"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?",
    "summary": "AstraZeneca stock is up 15% so far in 2025 as blockbuster drugs and a robust oncology portfolio fuel growth despite looming headwinds.",
    "url": "https://finnhub.io/api/news?id=d31d6edd9854fc45e63b74d7037b162c23113955d0eef5fe36364406db0eaaf8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758815520,
      "headline": "AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?",
      "id": 136884808,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "AstraZeneca stock is up 15% so far in 2025 as blockbuster drugs and a robust oncology portfolio fuel growth despite looming headwinds.",
      "url": "https://finnhub.io/api/news?id=d31d6edd9854fc45e63b74d7037b162c23113955d0eef5fe36364406db0eaaf8"
    }
  },
  {
    "ts": null,
    "headline": "AZN, Daiichi's Enhertu sBLA Gets FDA Priority Review for Breast Cancer",
    "summary": "AstraZeneca and Daiichi's Enhertu wins FDA priority review in breast cancer, backed by phase III data showing a 44% lower progression risk.",
    "url": "https://finnhub.io/api/news?id=7ed014ff868406eed30f0f521ee6364e01ff8eee4f5da7c2dfbd3246ec462bc4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758813600,
      "headline": "AZN, Daiichi's Enhertu sBLA Gets FDA Priority Review for Breast Cancer",
      "id": 136884811,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "AstraZeneca and Daiichi's Enhertu wins FDA priority review in breast cancer, backed by phase III data showing a 44% lower progression risk.",
      "url": "https://finnhub.io/api/news?id=7ed014ff868406eed30f0f521ee6364e01ff8eee4f5da7c2dfbd3246ec462bc4"
    }
  },
  {
    "ts": null,
    "headline": "Evaxion Rises After Licensing Vaccine Candidate to Merck & Co.",
    "summary": "Evaxion Rises After Licensing Vaccine Candidate to Merck & Co.",
    "url": "https://finnhub.io/api/news?id=b311b9ff742a5a703a5ddeeadb9c8658e8337650d1e93c9881068bc83077d1ba",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758813300,
      "headline": "Evaxion Rises After Licensing Vaccine Candidate to Merck & Co.",
      "id": 136922329,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Evaxion Rises After Licensing Vaccine Candidate to Merck & Co.",
      "url": "https://finnhub.io/api/news?id=b311b9ff742a5a703a5ddeeadb9c8658e8337650d1e93c9881068bc83077d1ba"
    }
  },
  {
    "ts": null,
    "headline": "Dow falls 175 points on losses for Amgen, Nike shares",
    "summary": "Dow falls 175 points on losses for Amgen, Nike shares",
    "url": "https://finnhub.io/api/news?id=6855a510b8868ab107f880cc8faaf8b9948ba942ab8bb84b352392ae2c37b519",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758812580,
      "headline": "Dow falls 175 points on losses for Amgen, Nike shares",
      "id": 136920811,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Dow falls 175 points on losses for Amgen, Nike shares",
      "url": "https://finnhub.io/api/news?id=6855a510b8868ab107f880cc8faaf8b9948ba942ab8bb84b352392ae2c37b519"
    }
  },
  {
    "ts": null,
    "headline": "Dow down 311 points on losses for shares of Nike, Amgen",
    "summary": "Dow down 311 points on losses for shares of Nike, Amgen",
    "url": "https://finnhub.io/api/news?id=aedca9afb9d4415a8f487174aaa61e100f6bc2d7907ddaa478b220957238799b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758808920,
      "headline": "Dow down 311 points on losses for shares of Nike, Amgen",
      "id": 136922032,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Dow down 311 points on losses for shares of Nike, Amgen",
      "url": "https://finnhub.io/api/news?id=aedca9afb9d4415a8f487174aaa61e100f6bc2d7907ddaa478b220957238799b"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Merck (MRK) is a Strong Value Stock",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finnhub.io/api/news?id=ccc927a39513449317822d16ea3cbf9641aa37a3b66b89d25989220d5fbad697",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758807602,
      "headline": "Here's Why Merck (MRK) is a Strong Value Stock",
      "id": 136883081,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "url": "https://finnhub.io/api/news?id=ccc927a39513449317822d16ea3cbf9641aa37a3b66b89d25989220d5fbad697"
    }
  },
  {
    "ts": null,
    "headline": "Evaxion Biotech Out-Licenses Vaccine Candidate to Merck; Shares Rise Pre-Bell",
    "summary": "Evaxion Biotech (EVAX) said Thursday it out-licensed its vaccine candidate EVX-B3 to Merck (MRK) in",
    "url": "https://finnhub.io/api/news?id=ddca473809c76fafcd6a5c2e23acf71cd14334d757888e46b5163128c1cba864",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758801770,
      "headline": "Evaxion Biotech Out-Licenses Vaccine Candidate to Merck; Shares Rise Pre-Bell",
      "id": 136883082,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Evaxion Biotech (EVAX) said Thursday it out-licensed its vaccine candidate EVX-B3 to Merck (MRK) in",
      "url": "https://finnhub.io/api/news?id=ddca473809c76fafcd6a5c2e23acf71cd14334d757888e46b5163128c1cba864"
    }
  },
  {
    "ts": null,
    "headline": "Germany’s Merck KGaA Names Kai Beckmann as Incoming Chair, CEO",
    "summary": "Germany’s Merck named Kai Beckmann as its incoming CEO and chair of the board, and said he would replace Belen Garijo from May.",
    "url": "https://finnhub.io/api/news?id=e6ce26295a765ab64b5756286b14884794a518b16402f265ce6af3b51ee122f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758799020,
      "headline": "Germany’s Merck KGaA Names Kai Beckmann as Incoming Chair, CEO",
      "id": 136883083,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Germany’s Merck named Kai Beckmann as its incoming CEO and chair of the board, and said he would replace Belen Garijo from May.",
      "url": "https://finnhub.io/api/news?id=e6ce26295a765ab64b5756286b14884794a518b16402f265ce6af3b51ee122f1"
    }
  },
  {
    "ts": null,
    "headline": "Merck: 25% Total Return CAGR Potential",
    "summary": "Discover why Merck (MRK) is a Strong Buy with robust growth, 4% yield, and 25% return potential.",
    "url": "https://finnhub.io/api/news?id=068d6c428d14b9582a0e09369f73c112862ae5dec63d66cb3921b808fd1c30de",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758797671,
      "headline": "Merck: 25% Total Return CAGR Potential",
      "id": 136882520,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover why Merck (MRK) is a Strong Buy with robust growth, 4% yield, and 25% return potential.",
      "url": "https://finnhub.io/api/news?id=068d6c428d14b9582a0e09369f73c112862ae5dec63d66cb3921b808fd1c30de"
    }
  },
  {
    "ts": null,
    "headline": "Keros Therapeutics: A Potential Dart Throw",
    "summary": "Keros Therapeutics: A Potential Dart Throw",
    "url": "https://finnhub.io/api/news?id=05f410b7ecb3b6b6b28725ebf01030ba919cab82defec639b4f33328826534eb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758795349,
      "headline": "Keros Therapeutics: A Potential Dart Throw",
      "id": 136882436,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=05f410b7ecb3b6b6b28725ebf01030ba919cab82defec639b4f33328826534eb"
    }
  },
  {
    "ts": null,
    "headline": "Evaxion Licenses EVX-B3 Vaccine Candidate to Merck",
    "summary": "Evaxion Licenses EVX-B3 Vaccine Candidate to Merck",
    "url": "https://finnhub.io/api/news?id=ae05059922981a3a8c1c5a165b54e9412a99ee17d674dc79956cec649f93c301",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758785640,
      "headline": "Evaxion Licenses EVX-B3 Vaccine Candidate to Merck",
      "id": 136922332,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Evaxion Licenses EVX-B3 Vaccine Candidate to Merck",
      "url": "https://finnhub.io/api/news?id=ae05059922981a3a8c1c5a165b54e9412a99ee17d674dc79956cec649f93c301"
    }
  }
]